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The development of an effective vaccine against HIV has proved to be difficult. Many 
factors including natural regulatory T cells (Treg cells) can dampen the CD8 T-cell immu-
nogenicity. In this study, we aimed to understand how Treg cells control CD8+ T-cell 
immune responses during DNA prime-boost immunization. Animals were immunized 
with plasmid HIV IIIB gp120 DNA following elimination of Treg cells by administration of 
anti-CD25 neutralizing antibody. Results demonstrated that the pool size of CD4+ T cells 
producing both IL-2 and/or IFN-γ (CD4+/IL-2+/IFN-γ+) was increased solely during the 
priming phase. An increment of tetramer binding and intracellular cytokine IFN-γ expres-
sion, however, were elevated in both primary and secondary stages in CD8+ T cells. The 
speed of antigen clearance was also investigated by using DNA luciferase. Surprisingly, 
DNA luciferase expression was declined to basal level over the ensuing observation 
period when Treg cells were depleted. Importantly, we found for the first time that DNA 
expression pattern in Treg-depleted animals was similar to that of the regular memory 
phase. Moreover, in mice that were exposed to antigen over 5 days prior to Treg cell 
depletion, CD8+ T-cell memory response was not affected. Thus, in the present study, 
we propose a new concept and prove that the enhanced immune response following 
the depletion of Treg cells during the priming phase likely adds one more set of memory 
response to the immune system. Taken together, our findings support the notion that 
Treg cells control DNA vaccine immunogenicity at an early time via antigen duration and 
functional CD4+ T-cell responses.
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introduction
Gaining a better understanding of the mechanisms guiding the generation and differentiation of 
effector and memory CTL remains a top priority in vaccinology and immunology.
While enormous advances have been made in recent years in understanding how immune 
responses are initiated and amplified, harnessing that understanding to improve vaccines has proven 
difficult (1, 2). Plasmid DNA immunogens are potential candidates in the design of an effective HIV 
vaccine (3). However, clinical trials of DNA vaccines have shown that the immunogenicity is much 
lower than conventional protein- or carbohydrate-based human vaccines, suggesting that a variety 
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of unknown factors are at work. In order to develop a vaccine with 
an effective CTL immune response, we have to consider several 
factors, such as the ability of Treg cells to suppress immune activa-
tion (4), the help of CD4+ T cells to initiate immune response 
(5–7), and the duration of antigen stimulation (2, 5–10). Since it is 
known that counterregulatory mechanisms can lower the capac-
ity to mount an effective immune response, controlling these 
regulatory mechanisms would potentially enhance the efficacy of 
vaccines and the management of chronic infections (4).
Natural regulatory T cells (Foxp3+CD25+CD4+ T cells, Treg 
cells) have been implicated in counterregulatory mechanisms, 
and accumulating evidence suggests that controlling their growth 
and proliferation may improve immunogenicity. For example, a 
number of mechanisms that boost immune responses and favor 
the control of pathogens also abrogate natural Treg cell function 
(4). In addition, a growing body of literature demonstrates that 
a distinct population of Treg cells is crucial for regulating the 
magnitude and specificity of immunity against a large number 
of infections (4), including many life-threatening diseases such 
as AIDS, TB, hepatitis C virus infection, and malaria (11–15). 
Strategies that manipulate natural Treg cells function or abun-
dance have shown therapeutic and preventive potentials (16, 
17). For a number of infections, in both mice and humans, the 
depletion of Treg cells or molecules associated with their func-
tions has resulted in enhanced effector immune responses (11, 
13, 17). More recently, studies have also confirmed the role of 
Treg cells by the use of genetically engineered Foxp3-DTR mice 
in several laboratories to study the specific role of Treg cells in 
primary and memory T-cell responses following vaccination and/
or infection (18, 19).
In light of previous studies, we sought to understand the role 
by which Treg cells restrain CD8+ T-cell immune responses to a 
specific DNA vaccine. We drastically reduced Treg cell popula-
tion through the administration of anti-CD25 antibody in mice 
to measure their antigenic responses to plasmid luciferase and 
immunogenicity to the HIV DNA vaccine, respectively. Apart 
from the augment of immune response to the DNA vaccine, we 
have shown for the first time that the DNA expression pattern 
is similar to the one of the regular memory response when Treg 
cells are depleted. We conclude that Treg cells modulate CD8+ 
T-cell immunogenicity via control of antigen duration and func-
tional CD4+ T-cell response during the early stage of immune 
response. Given the depletion of Treg cells during priming phase, 
the enhanced immune response is likely adding one more set of 
memory responses to the immune system.
results
Kinetics of Tregs cells Following administration 
of anti-cD25 Monoclonal antibody
Foxp3, described as a critical gene for Treg cells development and 
suppression function, is the most widely accepted signature of 
Treg cells (20, 21). We examined the distribution of Treg cells 
(CD4+CD25+Foxp3+ cell) in adult BALB/c mice in different 
compartments such as peripheral blood (PBL), spleen (SPL), 
and drain lymph nodes (dLN) in adult mice (Figures  1A,B). 
Thirty days later, following anti-CD25 treatment, Treg cells were 
gradually replenished in all three compartments including PB, 
SP, and dLNs. Within 3 months following injection of anti-CD25 
antibody, Tregs cells in all three studied compartments recovered 
completely (Figure  1C). We did not see any autoimmune-like 
symptoms exhibited in anti-CD25 antibody injected mice such 
as weight loss, skin rashes, and increased hair loss.
Pretreatment with anti-cD25 antibody During 
Priming Phase Yields significantly enhanced 
immune responses to Plasmid gp120 Dna
Animals were injected with the gp120 DNA following adminis-
tration of anti-CD25 Ab or control antibody, the percentages of 
H-2Dd/p18 tetramer (p18 tetramer) binding in CD8+ T cells from 
PBMCs were determined by weekly following DNA inoculation. 
At day 14 following DNA vaccine inoculation, anti-CD25 treated 
animals had a significantly higher percentage of p18 tetramer 
binding in CD8+ T cells (p < 0.05, Student’s t-test) (Figures 2A–D). 
No responses were observed in mice that received anti-CD25 
antibody alone (data not shown).
immune response of homologous Prime-Boost 
Vaccine is augmented by Treatment with anti-
cD25 antibody Prior to Priming Vaccination
To examine the effect of anti-CD25 antibody administration, 
strategy of homologous prime-boost vector-based vaccines was 
employed. Three days prior to vaccinations, groups of BALB/c 
mice were injected with anti-CD25 Ab or controls by i.p., and 
then received plasmid gp120, i.m. At 6 weeks after priming, mice 
were boosted with the same plasmid gp120 that was used for 
priming, and p18 tetramer-specific CD8+ T cells from PBMCs 
were analyzed weekly after boosting. We demonstrated that, at 
the indicated time points (weeks 2 and 3 following boost), mice 
receiving anti-CD25 had elevated tetramer binding response 
(Figures 2B–D) (p < 0.05, Student’s t-test).
Mice Pretreated with anti-cD25 antibody Prior 
to Priming Vaccination augments heterologous 
Prime-Boost Vaccine immunogenicity
To assess the magnitude of immune response to gp120 DNA 
vaccine during heterologous prime-boost vaccine strategy in 
anti-CD25 Ab pretreated animals, mice were boosted with 
recombined adenovirus gp140 DNA (rAd5 gp140), 6  weeks 
later following priming with gp120 DNA construct. Tetramer 
binding in CD8+ T cells was statistically higher at all time points 
after day 14 (p < 0.05, Student’s t-test) in CD25-depleted mice 
(Figures 2C,D).
increase in the Percentage of cD62l expression 
in P18 Peptide-specific cD8+ T cells after Treg 
cells Depletion in Mice
CD62L is one of the most prominently cited markers of recent 
antigen stimulating and homing for T-cell trafficking in  vivo, 
which is also a marker for memory response development 
(22). To explore the expression of this molecule, kinetics of 
antigen-specific CD8+ T cells in PBMCs from multiple lymph 
nodes, including inguinal, mesenteric, and brachial, was studied. 
FigUre 1 | Depletion of Foxp3+cD4+cD25+ T cells from Balb/c mice after in vivo treatment with Pc61 anti-cD25 mab. Mice (n = 6 mice/group) were 
given a dose of 1 mg of PC 61 anti-CD25 monoclonal antibody i.p., and Foxp3+ CD4+CD25+ T cells (Treg cells) were monitored by flow cytometry at indicated time 
points. (a) Efficacy of Treg cell depletion. Plots were day 3 data following injection of anti-CD25 antibody, Foxp3+ CD4+CD25+ T cells were detected from peripheral 
blood (PBL), spleen (SPL), and draining lymph nodes (dLN). Results shown are representative of three experiments performed. (B) The distribution of Foxp3+ 
CD4+CD25+ T cells in naive mice. The percentages of Foxp3+ CD4+CD25+ T cells were detected from peripheral blood (PBL), spleen (SPL), and draining lymph 
nodes (dLN). Data are shown as mean ± SE. (c) Indicated time points show the kinetics of gradual replenishment of Foxp3+CD4+CD25+ T cells in PBL, SPL, and 
dLN following anti-CD25 injection. Data are shown as mean ± SD. Results are representative of two experiments performed.
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Following inoculation of the plasmid gp120 DNA, CD62L+H-2Dd/
p18 tet+ CD8+T cells in CD25-depleted mice reached a maximum 
at 14 days (p < 0.01, Student’s t-test) and declined significantly 
thereafter after homologous boost (Figure 3B). Compared to the 
boost phase, the pattern in the priming phase was slightly differ-
ent: CD62L+H-2Dd/p18 tet+ CD8+ T cells in CD25-depleted mice 
was significantly higher than in non-depleted mice at days 14 
and 21 following plasmid DNA vaccine immunization (p < 0.05, 
Student’s t-test) (Figure 3A).
Treg cells Depletion leads to improved cD4+ 
T-cell response to gp120 Vaccine
CD4+ T cells play a prominent role in enabling CD8+ T-cell 
activation, proliferation, and differentiation. They are also 
critical for CD8+ T-cell memory formation and maintenance. 
By producing IL-2, CD4+ T cells are thought to be necessary 
for programming the differentiation of fully functional CD8+ 
T-cell memory (5, 6, 23). In this study, we addressed the ques-
tion of how Treg cells affect CD4+ T-cell function by detecting 
IL-2 and IFN-γ intracellularly. We harvested splenocytes at day 
14 post vaccine inoculation, following a 6-h exposure to a pool 
of peptides spanning the gp120 protein. A one-way ANOVA 
showed the differences between the CD25-depleted and non-
depleted animals. Significantly higher levels of IL-2, IFN-γ, and 
the poly IL-2+/IFN-γ+-CD4+ T cells were recorded in the prim-
ing phase in Treg cell-depleted mice (Figures 4A,C) (p < 0.05, 
one-way ANOVA). No difference for these cytokine expressions 
was demonstrated in memory phase (Figure  4B) (p >  0.05, 
one-way ANOVA). These data suggest that early CD4+ T-cell 
function is of critical importance for the establishment of an 
effective CD8+ T-cell response (24).
Functional cD8+ T-cell immune response to 
gp120 Dna immunogen is improved in Treg 
cells Depleted Mice
To determine whether the depletion of Treg cells had an influ-
ence on CD8-T cell function, we harvested splenocytes at day 
14 post vaccine administration both in the priming and boost 
phases. We observed that the cell population producing IFN-γ 
in CD8+ T cells stimulated by the p18 peptide was significantly 
increased in Treg cell-depleted mice in both priming and 
memory phases (p < 0.05, one-way ANOVA) (Figures 5A–C). 
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However, no statistically significant differences were detected 
in IL-2 and IL-2/IFN-γ polyfunctional cell populations 
detected, neither in the priming phase nor in the memory 
phase (Figures 5A–C).
FigUre 2 | enhancement of antigen-specific cD8+ T-cell responses following depletion of natural Foxp3+cD4+cD25+ Treg cells in hiV-iiiB gp120 
Dna immunization. Kinetics of H-2Dd/p18 tetramer staining of peripheral blood CD8+ T cells was monitored following depletion of natural FoxP3+CD4+CD25+ Treg 
cells. Data shown are representative of three experiments performed. Sham was used as an empty DNA with the same background as the DNA encoded HIVIIIB 
gene (refer to Materials and Methods). (a) Groups of mice (n = 4 mice/group) were first pretreated with either anti-CD25 mAb or control antibody in day 3 and in day 
0 intramuscularly injected with 50 μg plasmid gp120 DNA vaccine construct. Tetramer for H-2Dd/P18-specific CD8+ T-cell binding was then monitored at indicated 
time points (by weekly). The Treg cells depleted group had a threefold higher tetramer binding level in primary than the one in the control group at days 14 following 
plasmid gp120 inoculation (p < 0.05; Student’s t-test). (B) On day 42, mice (n = 4/group) previously immunized with gp120 DNA were boosted with homologous 
plasmid gp120 DNA. (c) Heterologous rAdv gp140 vaccine-elicited cellular immune responses were measured by tetramer binding to CD8+ T lymphocytes. Data 
are shown as mean ± SE. Arrows indicate boost immunizations. (D) Representative flow plots display percentages of CD8+tetramer+ T cells in the PBMCs between 
CD25-depleted and non-depleted groups at each time point of the injected mice. Plots are shown for the primary response (upper panel), homologous boost 
(middle panel), and the heterologous boost response (lower panel).
FigUre 3 | increases the percentage of cD62l expression in P18 
peptide-specific cD8+ T cells after Treg cells depletion in mice. 
Multiple lymph nodes including inguinal, mesenteric, and brachial obtained 
from groups of mice (n = 4 mice/group). (a) At day 0, Treg cells were 
depleted by administration of anti-CD25 antibody, and at day 3, plasmid 
gp120 DNA was injected. CD62L-specific tetramer-positive CD8+ T cells 
were measured. Differences in frequencies of tetramer in CD8 lymphocytes 
were statistically higher between 14 and 21 days (Student’s t-test with a 
cutoff of p = 0.05). (B) Mice at day 42 following gp120 DNA priming, then 
homologous gp120 DNA was boosted, the percentage of the gp120 
antigen-specific H-2Dd/p18+CD62L+CD8+ T cells frequencies was monitored 
weekly, at 14 days following inoculation of DNA vaccine reached a maximum 
and was statistically higher in CD25 injected group (p < 0.01, Student’s 
t-test). Data are expressed as the mean percentage ± SE. Results shown are 
representative of three experiments performed.
Depletion of Treg cells shortens the Duration of 
Dna antigen expression
Previous report has shown that responses in CD4+ T cells 
rather than CD8+ T cells were more dependent on antigens in 
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proliferation (25). For CD8+ T cells, the development of long-lived 
memory with protective capacity was all programmed within the 
first 1–2 days of acute infection (7, 10, 26). To explore whether 
DNA antigen expression may also be affected by Treg cells, we 
first depleted Treg cells, and then injected mice with a plasmid 
that expressed luciferase. Luciferase expression was monitored 
by IVIS over the ensuing 28 days (Figure 6A), and the average 
luciferase expression was evaluated. To our surprise, luciferase 
expression reduced more drastically in the Treg cell-depleted 
mice (Figures 6A,B). Significantly decreased antigen expression 
was seen as early as day 1 with an extension to day 14 (p < 0.05, 
Student’s t-test). We then compared this expression pattern to 
regular memory phases including homologous (Figure 6C) and 
heterologous (Figure  6D) luciferase boost strategies. For this 
study, two groups of mice were first primed with DNA luciferase 
(DNA-Luc) and Adv encoded luciferase by i.m., respectively. 
Luciferase expressions were monitored at different time points 
as indicated in Figure 6 (Figures 6C,D). After 6 weeks (42 days), 
these two groups of mice were respectively boosted to inject 
with 50  μg DNA-Luc, i.m., the expressions of luciferase were 
continuously to be monitored following the ensuing observa-
tions. Surprisingly, in homologous boosted mice (Figure  6C), 
luciferase expressions were only detected in a very short time 
(less than 10  days) and showed with lower expression values 
compared to the priming phase. Almost no luciferase expressions 
were detected in heterologous boosted group (Figure 6D). This 
shortened antigen expression pattern in the memory phases was 
very similar to the one in a single Treg cell-depleted mice model 
in priming phase (Figure 6A).
Treg cell Does not affect cD8+ T-cell Memory 
response Following exposure to gp120 over 
5 Days
Having seen that Treg cells depletion prior to antigen exposure 
could enhance CD8+ T cells in both priming and memory phases, 
we were prompted to investigate whether Treg cells would affect 
immunogenicity following antigen exposures. Experiments were 
then designed to assess the tetramer binding ability in CD8 T 
cells. Five groups of mice were all immunized with gp120 DNA 
vaccine at day 0 first. With the exception of one group left as the 
DNA vaccine control, the four remaining groups of mice then 
respectively received anti-CD25 Abs at days 0, 2, 5, and 7 fol-
lowing plasmid gp120 immunizations. We found that, in groups 
of day 0 (gp120 and anti-CD25 antibody coinjected) and day 2 
(mice received anti-CD25 Abs 2  days following DNA vaccine 
injection), CD8+ T-cell responses were all augmented both in 
priming and memory phases at indicated time points (Figure 7) 
(p < 0.05, Student’s t-test). Dunnett’s multiple comparison tests 
with a cutoff of p = 0.05 showed immune responses to be signifi-
cantly higher in animals in the day 2 group during the primary 
phase. For day 5 and day 7 groups, no boosted effects were seen 
in animals (Figure 7), suggesting that Treg cells may have earlier 
effects on regulation of CD8+ T-cell immune responses.
Discussion
The development of an effective vaccine against HIV has proved 
to be difficult, owing to our limited knowledge of the protective 
immunity needed to contract the infection. In order to develop 
vaccines against diseases such as AIDS, malaria, and tuberculosis, 
it is crucial to understand and to optimize the development of 
CTL responses to vaccines. More specific models such as geneti-
cally engineered Foxp3-DTR mice have been employed by several 
laboratories to study the specific role of Treg cells in primary and 
memory T-cell responses (18, 19). The major concern for deple-
tion of Treg cells is the induction of autoimmunity. However, 
recent reports have shown some contradictions, by blockade or 
transient depletion of CD25 using the FDA-approved anti-CD25 
antibody (Daclizumab): researchers do see an enhancement of 
immunity (27) but without induction of autoimmunity in cancer 
patients (27, 28). Nevertheless, more recent studies have also 
shown promising results by targeting the interaction between 
However, no statistically significant differences were detected 
in IL-2 and IL-2/IFN-γ polyfunctional cell populations 
detected, neither in the priming phase nor in the memory 
phase (Figures 5A–C).
FigUre 2 | enhancement of antigen-specific cD8+ T-cell responses following depletion of natural Foxp3+cD4+cD25+ Treg cells in hiV-iiiB gp120 
Dna immunization. Kinetics of H-2Dd/p18 tetramer staining of peripheral blood CD8+ T cells was monitored following depletion of natural FoxP3+CD4+CD25+ Treg 
cells. Data shown are representative of three experiments performed. Sham was used as an empty DNA with the same background as the DNA encoded HIVIIIB 
gene (refer to Materials and Methods). (a) Groups of mice (n = 4 mice/group) were first pretreated with either anti-CD25 mAb or control antibody in day 3 and in day 
0 intramuscularly injected with 50 μg plasmid gp120 DNA vaccine construct. Tetramer for H-2Dd/P18-specific CD8+ T-cell binding was then monitored at indicated 
time points (by weekly). The Treg cells depleted group had a threefold higher tetramer binding level in primary than the one in the control group at days 14 following 
plasmid gp120 inoculation (p < 0.05; Student’s t-test). (B) On day 42, mice (n = 4/group) previously immunized with gp120 DNA were boosted with homologous 
plasmid gp120 DNA. (c) Heterologous rAdv gp140 vaccine-elicited cellular immune responses were measured by tetramer binding to CD8+ T lymphocytes. Data 
are shown as mean ± SE. Arrows indicate boost immunizations. (D) Representative flow plots display percentages of CD8+tetramer+ T cells in the PBMCs between 
CD25-depleted and non-depleted groups at each time point of the injected mice. Plots are shown for the primary response (upper panel), homologous boost 
(middle panel), and the heterologous boost response (lower panel).
FigUre 3 | increases the percentage of cD62l expression in P18 
peptide-specific cD8+ T cells after Treg cells depletion in mice. 
Multiple lymph nodes including inguinal, mesenteric, and brachial obtained 
from groups of mice (n = 4 mice/group). (a) At day 0, Treg cells were 
depleted by administration of anti-CD25 antibody, and at day 3, plasmid 
gp120 DNA was injected. CD62L-specific tetramer-positive CD8+ T cells 
were measured. Differences in frequencies of tetramer in CD8 lymphocytes 
were statistically higher between 14 and 21 days (Student’s t-test with a 
cutoff of p = 0.05). (B) Mice at day 42 following gp120 DNA priming, then 
homologous gp120 DNA was boosted, the percentage of the gp120 
antigen-specific H-2Dd/p18+CD62L+CD8+ T cells frequencies was monitored 
weekly, at 14 days following inoculation of DNA vaccine reached a maximum 
and was statistically higher in CD25 injected group (p < 0.01, Student’s 
t-test). Data are expressed as the mean percentage ± SE. Results shown are 
representative of three experiments performed.
FigUre 4 | intracellular staining for il-2 and iFn-γ in cD4+ T cells. Groups of mice (n = 4 mice/group) Treg cells depleted at day 3 and non-depleted, plasmid 
gp120 DNA was injected (a) or (B) boosted on day 42 with homologous gp120 DNA. On day 14 following priming or post boost, mice were sacrificed and 
splenocytes were harvested, isolated, and exposed for 6 h to a pool of 47 overlapping peptides spanning the HIV-IIIB gp120 protein (2 μg/ml) or to media alone. The 
frequencies of intracellular IFN-γ+ CD4+ T cells, IL-2+CD4+ T cells, and IFN-γ+ IL-2+ polyfunctional CD4+ T cells were measured by an LSRII Flow machine, all 
cytokines show higher frequencies (p < 0.05) in CD25 depleted during primary phase, but not in boosted phase as determined by one-way ANOVA test.  
(c) Representative flow plots are shown with percentages in IL-2+ (upper panel), IFN-γ-positive (middle panel), and IL-2/IFN-γ double-positive populations in CD4 T 
lymphocytes. Numbers indicate the percentages of these cell populations and representative of the means of four mice per group ± SE. Results shown are 
representative of three experiments performed.
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CCR4 expressed on Tregs cells and its ligands, CCL22 and 
CCL17, to inhibit transiently the recruitment of Tregs at the site of 
immunization. Importantly, this activity was observed in diverse 
models without noticeable side effects of autoimmunity. As CCR4 
is also expressed on a variety of immune cells, including DCs and 
B cells, they may also deplete these kinds of cells (for details please 
see a review written by Bayry et al.) (29). Therefore, further study 
of the function of Treg cells including the mechanisms will merit 
its potential applications by avoiding potential feedbacks such as 
autoimmunity.
Regulatory T cells participate in the immune response to many 
and/or all infectious agents and immunogens. Although Treg cells 
can respond to a large variety of self-antigens, these responses 
may decrease the efficacy of protective immunity. Accumulating 
evidence indicates that immunity to viral infections such as 
HSV, HIV, and HCV are partially controlled by natural Treg cells 
including the efficacy of vaccines (30, 31). Depletion of Treg cells 
has been shown to enhance CD4+ T cells (11, 15), CD8+ T cells 
(26, 30–33), or both CD4+ and CD8+ T-cell responses (12, 13, 
34). Likewise, Treg cells have also been reported to control the 
intensity and magnitude of secondary responses to infectious 
pathogens such as Listeria, Leishmania, and HSV (31–33). In the 
present study, we have demonstrated that, in the absence of Treg 
cells, enhanced immune responses were paralleled with increased 
FigUre 5 | intracellular staining for il-2 and iFn-γ in cD8+ T cells. Groups of mice (n = 4 mice/group) with Treg cells depleted or non-depleted were first 
primed with plasmid gp120 DNA (a) or (B) boosted on day 42 with homologous gp120 DNA. On day 14 following priming or post boost, mice were sacrificed and 
splenocytes were harvested, isolated, and exposed for 6 h to the p18 peptides (2 μg/ml) or media alone. The percentage of intracellular IFN-γ+ CD8+ T cells, 
IL-2+CD8+ T cells, and IFN-γ+ IL-2+ dual function CD8+T cells was measured on a LSRII flow machine, we only see a statistically higher IFN-γ populations in both 
primary and memory phases (p < 0.05, one-way ANOVA test). Numbers indicate the percentages of these cell populations and representative of the means ± SE. 
(c) Representative flow plots are shown with percentages of IL-2-positive (upper panel), IFN-γ-positive (middle panel), and IL-2/IFN-γ double-positive populations in 
CD8 lymphocytes. Results shown are representative of three experiments performed.
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antigen-specific CD62L+H-2Dd/p18 tet+ CD8+ T-cell population 
during both primary and memory phases. This is well in agree-
ment with the notions that the cells survived contraction for seed-
ing the memory pool (memory precursor) and may have already 
been presenting at the peak of expansion (Figure  3) (35, 36). 
This population may contribute greatly to the enlargement of the 
antigen-specific memory pool (Figure 3) (4, 35). A more recent 
study by Buchholz et  al. (37) suggested that families showing 
greater expansion contained more effector and effector memory 
T cells, whereas small families were predominantly composed of 
central memory T cells. This study has also indicated that the fate 
of single naive CD8+ T cells is determined at an early stage by 
either random internal variation between individual naive T cells 
or by random (external) variation in the environmental cues that 
they receive (37). Our present study is very well in line with their 
findings. We have shown in the absence of Treg cells enhanced 
CD8 T-cell responses (Figure 2A), and CD4 T cells at an early 
time (i.e., the priming phase) produce larger number of IL-2 and 
IFN-γ (Figure 4A), which might be useful in helping to establish-
ing robust immune responses during memory stimulations.
A number of mechanisms by which Treg cells contribute to the 
suppression of immune response have been extensively studied. 
One of the most notable consequences of the modulation of 
immune response is to enhance pathogen survival and a long-term 
persistence (4). Recent studies have confirmed and added to the 
concept that a relatively short encounter with antigen may launch 
CD8+ T cells into a program of proliferation and differentiation 
without continuous antigenic stimulation, under the assumption 
that the original signal could have already programmed the long-
term fate of the subsequent CTL population (38, 39). Consistent 
FigUre 6 | shortening Dna antigen duration by depletion of natural Treg cells prior to Dna luciferase immunization. (a) At day 3, mice (n = 4 mice/
group) were injected intraperitoneally with 1 mg of PC61 anti-CD25 monoclonal antibody, control antibody, or left as empty control group. At day 0, 50 μg plasmid 
luciferase was injected, and luciferase expressions were monitored by IVIS over the ensuing 28 days and were expressed as mean ± SD. Luciferase expression was 
significantly decreased from day 1 to day 14 during the ensuing 28 days’ observations in the anti-CD25 antibody injected group (p < 0.05, Student’s t-test).  
(B) Representative images of mice at day 2 and day 3, respectively, for luciferase expressions between CD25 depleted and non-depleted mice. (c) Mice (n = 4) 
were injected 50 μg DNA luciferase at both priming and recall phases (homologous boosted at day 42 following priming with DNA luciferase), respectively. IVIS 
monitoring at indicated time points. Dramatically reduced luciferase expression was determined at memory phase (less than 10 days). (D) Mice (n = 4) were injected 
108 adenovirus-encoded luciferase particles in priming phase; 42 days later, 50 μg DNA Luciferase (heterologous boost) was injected. Luciferase expressions were 
monitored by IVIS at indicated time points. The mean relative light unit (RLU) values expressed by groups of four mice ± SD.
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with this concept, we have shown that, in the absence of Treg 
cells, the DNA expression was disrupted from day 1 following 
the injection of plasmid luciferase during the ensuing observa-
tion period (Figure 6A). Interestingly, previous studies on T-cell 
memory response have drawn the conclusions that functional 
antigen-dependent CD8+ T-cell memory populations formed 
after acute infections, while chronic infections led to generation 
of inefficient or poor quality of CD8+ T-cell memory (40, 41). 
In fact, through the observation of DNA expression, we found 
for the first time that a shortened antigen duration occurred in 
the absence of Treg cells (Figure  6A), with this in  vivo DNA-
Luc expression displaying a pattern similar that of the regular 
memory response (Figures 6C,D). One important implication of 
this result is that it better explains why depletion of Treg cells is 
able to enhance immune response during pathogen invasions and 
immunogen vaccinations.
A number of mechanisms have been shown to limit the 
expression of vaccine vectors in vivo. We have previously shown 
that type I interferons can dampen DNA-Luc expression under 
the treatment of plasmid GM-CSF. In that study, the DNA-Luc 
used is exactly the same as in the present study (1). It is still 
unclear whether or not type I interferons can be one of the causa-
tive reasons to shorten the duration of the plasmid luciferase 
expression, as we did not check the type I interferon-production 
level following the depletion of Treg cells. Although immune-
mediated destruction of Ag-producing muscle fibers has been 
reported following immunization with plasmid DNA expressing 
a surface-expressed hepatitis B virus Ag (HBsAg), this destruc-
tion was not seen with a plasmid DNA expressing the intracellular 
protein luciferase (18). Herein, we have excluded the possibility 
that shortened antigen expression with such a rapid speed and 
short time is due to the specific clonal expanded CD8 T cells. 
Rather, our data are consistent with a mechanism by which the 
function of CD4 T cells influences the duration of depot antigen 
and the in vivo clearance of plasmid DNA (42). This study has 
also demonstrated that the control of DNA antigen expression 
can result in accelerated contraction, differentiation, and greater 
memory CD8 T-cell responses as well (42). Additionally, data 
from a previous study showed that Fas-mediated apoptosis 
limited in  vivo vaccine antigen expression (19). The reasons 
FigUre 7 | Tregs depletion following mice exposure to plasmid gp120 
at different time points. Groups of mice (n = 4 mice/group) were injected 
with plasmid gp120 first. Then at day 0, 2, 5, and 7 following inoculation, 
mice were injected with anti-CD25 neutralizing antibody, respectively. CD8 
T-cell responses were measured weekly by P18 tetramer bindings. Data are 
shown at day 0 and day 2 in anti-CD25-treated groups, CD8 T-cell memory 
responses were enhanced after boost 14 days (p < 0.05, Student’s t-test), 
while no memory responses boosted were seen for day-5 and day-7 groups. 
Results shown are representative of two experiments performed. Data are 
expressed as the mean percentages of tetramer-positive CD8+ T cells ± SE.
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why the luciferase antigen disappears more rapidly under anti-
CD25 treatment are still largely unknown. Further study will 
merit the elucidation of the mechanisms underlying antigen 
duration-associated immune responses. Indeed, in this study, in 
the absence of Treg cells, we have demonstrated a strong correla-
tion of enhancement of CD8+ T-cell responses with shortened 
DNA antigen duration in DNA vaccine in both priming and 
secondary phases, which also provided strong evidence to sup-
port the notion in memory T-cell development. In other words, 
depletion of Treg cells during priming phase, enhanced immune 
response is likely adding one more set of memory responses to 
the immune system.
Moreover, this notion is further supported by results of 
early-elevated intracellular cytokine profiles in CD4 T cells. As 
CD4+ T cells can play an essential role in response to primary 
antigen challenges for initially expanding CD8+ T cells (43), 
programming CD8+ T-cell differentiation into long-lived protec-
tive memory (44, 45). Consistent with this notion, our present 
work has shown that, by depletion of Treg cells (Figure  4), 
increased IFN-γ and IL-2 producing CD4+ T-cell populations 
only appeared in primary immunization. The results suggested 
that, early in the process of immune responses, these cytokines 
may play an important role in helping memory CD8 T-cell for-
mation. The expansion function of IFN-γ in Ag-specific T-cell 
populations has been extensively studied (46–49). As for IL-2, the 
essential factor for Treg cell survival, which has also been shown 
to be indispensable to program the differentiation into functional 
CD8+ T-cell memory at early time (50–52).
Despite the fact that numerous studies have been shown to 
enhance immune responses by depleting Treg cells, and although 
the anti-CD25 antibody has been approved used for therapeutic 
applications, the mechanisms underlying the adjuvant effects 
of anti-CD25 neutralizing antibody are still largely unknown. 
Herein, we are for the first time displaying that, by administra-
tion of anti-CD25 antibody, the pattern of DNA vaccine-induced 
immune response is similar to the one in a regular memory 
phase, which better explains why the depletion of Treg cells is 
able to enhance immune response during pathogen invasions and 
immunogen vaccinations.
Taken together, our findings support the conclusions that 
Treg cells control DNA vaccine immunogenicity at an early 
time via antigen duration and functional CD4+ T-cell responses. 
Depletion of Treg cells during priming phase-enhanced immune 
response is likely adding one more set of memory response to the 
immune system.
Materials and Methods
animals and immunizations
Six- to eight-week-old female Balb/c mice were obtained from 
The Jackson Laboratory (Bar Harbor, ME, USA) and Charles 
River Laboratories (Wilmington, MA, USA). Mice were 
maintained under pathogen-free conditions, and experimental 
protocols were approved by the Harvard Institutional Animal 
Care and Use Committee. For experiments conducted in 
China, all protocols were approved by the ethics committee of 
Shandong Academy of Medical Sciences (Jinan, China) and per-
formed in compliance with the EC regulations (O.J. of E.C.L358 
12/18/1986) and the NIH standards (Guide for the Care and Use 
of Laboratory Animals, National Institutes of Health’s publica-
tion 86-23, revised 1996). For plasmid DNA immunizations, 
50 μg of pVRC-HIV-1 Env IIIB gp120, the complete CXCR4-
tropic HIV-1 HXB2 Env IIIB (GenBank accession no. K03455), 
was cloned into the pVRC vector as previously described (42). 
Plasmid DNA was prepared using an endotoxin-free Qiagen 
Giga-prep kit (Qiagen, Valencia, CA, USA). rAdvgp140 and 
rAdv-luciferase were provided by Dr. Barouch. For immuniza-
tions, 50  mg of plasmid DNA in 100  ml of sterile saline was 
divided between quadriceps muscles by intramuscular (i.m.) 
inoculation. The plasmid DNA-Luc construct was prepared as 
previously described (53). This vector contains the GL4.10 lucif-
erase gene (Promega, Madison, WI, USA) or the empty pVRC 
plasmid (NIH Vaccine Research Center, Bethesda, MD, USA) 
were injected in 100 μl of sterile saline divided between the left 
and right quadriceps muscles (54).
antibodies and reagents
PC61 (anti-CD25) was purchased from Bioexpress (NH) 
for in  vivo administration. Antibodies purchased from BD 
Pharmingen were PerCP anti-CD8α (clone; 53-6.7), Alexa 
Flour 700 anti-IFN-γ (clone; XMG1.2), APC anti-IL-2 (Clone; 
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JHS6-5H4), and PE-Cy7 anti-CD4 (clone; GK1.5). Antibodies 
purchased from eBioscience were FITC anti-CD4 (RM4-5), APC 
anti-CD25 (eBio,7D4), and PE anti-Foxp3 FJK-16s.
Tetramer staining assay
Tetrameric H-2Dd complexes folded around the HIV-1 IIIB V3 
loop P18 epitope peptide (P18-I10 or RGPGRAFVTI) (1, 55) 
were prepared and used to stain P18-specific CD8+ T cells as 
previously described (53). Mouse blood was collected in RPMI 
1640 containing 40  U/ml heparin. Following lysis of RBCs, 
0.1 μg PE-labeled Dd/P18 tetramer in conjunction with APC-
labeled anti-mouse CD8 mAb (Ly-2, Caltag, San Francisco, 
CA, USA) was used to stain P18-specific CD8+ T cells. The 
cells were washed in PBS containing 2% FBS and fixed in 
0.5 ml PBS containing 1.5% paraformaldehyde. Samples were 
analyzed by LSRII flow machine (BD Biosciences, CA, USA) 
and gated CD8+ T cells were examined for staining with the 
H-2Dd/P18 tetramer.
FoxP3 T cells intracellular staining
Staining procedures followed the product instructions from 
eBioscience. Briefly, cells isolated from PBL, SPL and lymph node 
(about 1  million PBMC) were first subject to staining surface 
molecular for CD4 and CD25 for 20 min and then fixed and per-
meated using Cytofix/Cytoperm buffer (BD biosciences). Finally, 
cells were stained with PE-labeled, anti-mouse Foxp3 antibody 
and analyzed on an LSRII flow machine (BD Biosciences).
splenocyte stimulation and intracellular 
cytokine staining
Splenocytes harvested from individual mice and red blood 
cells were lysed by using ACK lysing buffer. The cells were 
then washed with PBS +  2% FBS, counted, and stained with 
PE-conjugated H-2Dd/p18 tetramer. The cells were then resus-
pended (4 × 106 cells per tube) in RPMI 1640 medium (Cellgro, 
Herndon, VA, USA) supplemented with 10% FBS, 25  mM 
HEPES, 2  mM l-glutamine, 20  U of penicillin per milliliter, 
20 μg of streptomycin per milliliter, 1 mM sodium pyruvate, and 
0.1  mM non-essential amino acids. For CD8+ T-cell stimula-
tion, cells were incubated with Golgi Plug (2 μl/ml), anti-CD28 
(2 μg/ml), anti-CD49d (2 μg/ml), and p18 peptide (2 μg/ml). 
For CD4+ T-cell stimulation, instead of the p18 peptide, the 
cells were incubated with 2 μg of Env peptide pool per mil-
liliter. The pool consisted of 47 overlapping 15-mer peptides 
spanning the HIV-1 IIIB gp120 protein (Centralized Facility 
for AIDS Reagents, Potters Bar, UK), and each peptide had a 
concentration of 2 μg/ml. Unstimulated cells were incubated 
with all the above reagents except for the peptides. As a posi-
tive control, splenocytes were incubated with PMA (2 μg/ml), 
ionomycin (10 μg/ml), and Golgi Plug. The cells were incubated 
at 37°C for 6 h and then washed with PBS + 2% FBS, stained 
with PE-conjugated H-2Dd/p18 tetramer for 15 min, followed 
by addition of antibodies specific for cell surface molecules 
for an additional 15  min. Permeabilization was performed 
overnight with Cytofix/Cytoperm solution (BD Biosciences). 
Cells were washed with 1× Perm/Wash buffer (BD Biosciences) 
and then stained with anti-cytokine mAb. After an additional 
washing step with 1× Perm/Wash buffer, the cells were fixed 
in 2% formaldehyde-PBS. Samples were collected on an LSR 
II instrument (BD Biosciences) and analyzed using FlowJo 
software (Tree Star).
In vivo Bioluminescence Measurement
Animals were injected i.p. with 100 μl of a 30 mg/ml solution 
of firefly luciferin in PBS (Xenogen, Alameda, CA, USA), 
100 μl of a 20  mg/ml ketamine, and a 1.72 μg/ml xylazine 
mixture (1). After 20 min, imaging was performed using the 
In  vivo Imaging System (IVIS) Series 100 (Xenogen) with 
an integration time of 1 min. Luminescence measurements 
were made using Living Image software (Version 2.50.1, 
Xenogen).
Depletion of Treg cells in Different Times 
Following exposure to antigen immunization
Following gp120 DNA vaccine immunization at day 0, 2, 5, 
and 7, 6- to 8-week-old female Balb/c mice were divided into 
four groups (n =  4) and i.p. injected 1  ml (concentration, 
1.0 mg/ml) anti-CD25 neutralizing antibody to observe the 
splenocytes priming and memory CD8+ T-cell responses by 
detecting CD8+ T cells for P18 tetramer binding.
statistics
The statistical significances of differences between groups 
were determined by Student’s t-test, one-way ANOVA, or 
Dunnett’s multiple comparison tests using the GraphPad 
Prism program (version 6.03). A value of p < 0.05 was consid-
ered statistically significant. Error bars represent the standard 
error or standard deviation of the mean as described in the 
figure legends.
author contributions
LQ designed and performed experiments and drafted the 
manuscript. GJ and JH analyzed part of the results, and NLL 
agreed to publish the data.
acknowledgments
We gratefully acknowledge Dr. Darrell J. Penta at Boston 
University, professor James Whitney and colleagues from Center 
for Virology and Vaccine Research, Beth Israel Deaconess 
Medical Center, Harvard Medical School, for critically reading 
this manuscript. This work was supported by the NIAID center 
for HIV/AIDS vaccine immunology grant (AI067854) and 
the Harvard University Center for AIDS Research (CFAR), an 
NIH-funded program (P30 AI060354) to NL. LQ was supported 
by the intramural Institutional Basic Medicine grant (2014-2), 
Shandong Academy of Medical Sciences grant (2014-11), and 
the Department of Health and Family-plan Bureau, Shandong 
Province (2014WS0068). Shandong Provincial College of 
Traditional Chinese Medicine Antiviral Collaborative Innovation 
Center (XTCX2014) to LQ and HM.
September 2015 | Volume 6 | Article 51011
Qin et al. Treg early regulation of immunogenicity
Frontiers in Immunology | www.frontiersin.org
references
1. Qin L, Greenland JR, Moriya C, Cayabyab MJ, Letvin NL. Effects of type I 
interferons on the adjuvant properties of plasmid granulocyte-macrophage 
colony-stimulating factor in  vivo. J Virol (2007) 81:10606–13. doi:10.1128/
JVI.01000-07 
2. Chen TC, Cobbold SP, Fairchild PJ, Waldmann H. Generation of anergic 
and regulatory T cells following prolonged exposure to a harmless antigen. 
J Immunol (2004) 172:5900–7. doi:10.4049/jimmunol.172.10.5900 
3. Boyer JD, Robinson TM, Kutzler MA, Vansant G, Hokey DA, Kumar S, et al. 
Protection against simian/human immunodeficiency virus (SHIV) 89.6P in 
Macaques after coimmunization with SHIV antigen and IL-15 plasmid. Proc 
Natl Acad Sci USA (2007) 104:18648–53. doi:10.1073/pnas.0709198104 
4. Sakaguchi S, Vignali DA, Rudensky AY, Niec RE, Waldmann H. The plas-
ticity and stability of regulatory T cells. Nat Rev Immunol (2013) 13:461–7. 
doi:10.1038/nri3464 
5. Jelley-Gibbs DM, Dibble JP, Filipson S, Haynes L, Kemp RA, Swain SL. 
Repeated stimulation of CD4 effector T cells can limit their protective func-
tion. J Exp Med (2005) 201:1101–12. doi:10.1084/jem.20041852 
6. Kaech SM, Ahmed R. Memory CD8+ T cell differentiation: initial antigen 
encounter triggers a developmental program in naive cells. Nat Immunol 
(2001) 2:415–22. doi:10.1038/87720
7. Prlic M, Blazar BR, Khoruts A, Zell T, Jameson SC. Homeostatic expansion 
occurs independently of costimulatory signals. J Immunol (2001) 167:5664–8. 
doi:10.4049/jimmunol.167.10.5664 
8. Radcliffe JN, Roddick JS, Stevenson FK, Thirdborough SM. Prolonged antigen 
expression following DNA vaccination impairs effector CD8+ T cell function 
and memory development. J Immunol (2007) 179:8313–21. doi:10.4049/
jimmunol.179.12.8313 
9. Swain SL, Agrewala JN, Brown DM, Jelley-Gibbs DM, Golech S, Huston G, 
et  al. CD4+ T-cell memory: generation and multi-faceted roles for CD4+ 
T cells in protective immunity to influenza. Immunol Rev (2006) 211:8–22. 
doi:10.1111/j.0105-2896.2006.00388.x 
10. van Stipdonk MJ, Lemmens EE, Schoenberger SP. Naive CTLs require a single 
brief period of antigenic stimulation for clonal expansion and differentiation. 
Nat Immunol (2001) 2:423–9. doi:10.1038/87730
11. Aandahl EM, Michaelsson J, Moretto WJ, Hecht FM, Nixon DF. Human 
CD4+ CD25+ regulatory T cells control T-cell responses to human immu-
nodeficiency virus and Cytomegalovirus antigens. J Virol (2004) 78:2454–9. 
doi:10.1128/JVI.78.5.2454-2459.2004 
12. Cabrera R, Tu Z, Xu Y, Firpi RJ, Rosen HR, Liu C, et al. An immunomodula-
tory role for CD4(+)CD25(+) regulatory T lymphocytes in hepatitis C virus 
infection. Hepatology (2004) 40:1062–71. doi:10.1002/hep.20454 
13. Kinter AL, Hennessey M, Bell A, Kern S, Lin Y, Daucher M, et al. CD25(+)
CD4(+) regulatory T cells from the peripheral blood of asymptomatic 
HIV-infected individuals regulate CD4(+) and CD8(+) HIV-specific T cell 
immune responses in vitro and are associated with favorable clinical markers 
of disease status. J Exp Med (2004) 200:331–43. doi:10.1084/jem.20032069 
14. Scott-Browne JP, Shafiani S, Tucker-Heard G, Ishida-Tsubota K, Fontenot JD, 
Rudensky AY, et al. Expansion and function of Foxp3-expressing T regula-
tory cells during tuberculosis. J Exp Med (2007) 204:2159–69. doi:10.1084/
jem.20062105 
15. Weiss L, Donkova-Petrini V, Caccavelli L, Balbo M, Carbonneil C, Levy Y. 
Human immunodeficiency virus-driven expansion of CD4+CD25+ regula-
tory T cells, which suppress HIV-specific CD4 T-cell responses in HIV-infected 
patients. Blood (2004) 104:3249–56. doi:10.1182/blood-2004-01-0365 
16. Andersson J, Boasso A, Nilsson J, Zhang R, Shire NJ, Lindback S, et al. The 
prevalence of regulatory T cells in lymphoid tissue is correlated with viral 
load in HIV-infected patients. J Immunol (2005) 174:3143–7. doi:10.4049/
jimmunol.174.6.3143 
17. Suvas S, Rouse BT. Treg control of antimicrobial T cell responses. Curr Opin 
Immunol (2006) 18:344–8. doi:10.1016/j.coi.2006.03.005 
18. Davis HL, Millan CL, Watkins SC. Immune-mediated destruction of trans-
fected muscle fibers after direct gene transfer with antigen-expressing plasmid 
DNA. Gene Ther (1997) 4:181–8. doi:10.1038/sj.gt.3300380 
19. Greenland JR, Geiben R, Ghosh S, Pastor WA, Letvin NL. Plasmid DNA 
vaccine-elicited cellular immune responses limit in  vivo vaccine antigen 
expression through Fas-mediated apoptosis. J Immunol (2007) 178:5652–8. 
doi:10.4049/jimmunol.178.9.5652 
20. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and 
function of CD4+CD25+ regulatory T cells. Nat Immunol (2003) 4:330–6. 
doi:10.1038/ni904 
21. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development 
by the transcription factor Foxp3. Science (2003) 299:1057–61. doi:10.1126/
science.1079490 
22. Kedzierska K, Stambas J, Jenkins MR, Keating R, Turner SJ, Doherty PC. 
Location rather than CD62L phenotype is critical in the early establishment 
of influenza-specific CD8+ T cell memory. Proc Natl Acad Sci USA (2007) 
104:9782–7. doi:10.1073/pnas.0703699104 
23. Janssen EM, Lemmens EE, Wolfe T, Christen U, von Herrath MG, Schoenberger 
SP. CD4+ T cells are required for secondary expansion and memory in CD8+ 
T lymphocytes. Nature (2003) 421:852–6. doi:10.1038/nature01441 
24. Fehervari Z, Yamaguchi T, Sakaguchi S. The dichotomous role of IL-2: 
tolerance versus immunity. Trends Immunol (2006) 27:109–11. doi:10.1016/j.
it.2006.01.005 
25. Obst R, van Santen HM, Mathis D, Benoist C. Antigen persistence is required 
throughout the expansion phase of a CD4(+) T cell response. J Exp Med 
(2005) 201:1555–65. doi:10.1084/jem.20042521 
26. Sugimoto K, Ikeda F, Stadanlick J, Nunes FA, Alter HJ, Chang KM. Suppression 
of HCV-specific T cells without differential hierarchy demonstrated ex vivo 
in persistent HCV infection. Hepatology (2003) 38:1437–48. doi:10.1016/j.
hep.2003.09.026 
27. Rech AJ, Mick R, Martin S, Recio A, Aqui NA, Powell DJ Jr, et  al. CD25 
blockade depletes and selectively reprograms regulatory T cells in concert 
with immunotherapy in cancer patients. Sci Transl Med (2012) 4:134ra62. 
doi:10.1126/scitranslmed.3003330 
28. Jacobs JF, Punt CJ, Lesterhuis WJ, Sutmuller RP, Brouwer HM, Scharenborg 
NM, et al. Dendritic cell vaccination in combination with anti-CD25 mono-
clonal antibody treatment: a phase I/II study in metastatic melanoma patients. 
Clin Cancer Res (2010) 16:5067–78. doi:10.1158/1078-0432.CCR-10-1757 
29. Bayry J, Tartour E, Tough DF. Targeting CCR4 as an emerging strategy 
for cancer therapy and vaccines. Trends Pharmacol Sci (2014) 35:163–5. 
doi:10.1016/j.tips.2014.02.003 
30. Dittmer U, He H, Messer RJ, Schimmer S, Olbrich AR, Ohlen C, et al. Functional 
impairment of CD8(+) T cells by regulatory T cells during persistent retroviral 
infection. Immunity (2004) 20:293–303. doi:10.1016/S1074-7613(04)00115-3 
31. Toka FN, Suvas S, Rouse BT. CD4+ CD25+ T cells regulate vaccine-generated 
primary and memory CD8+ T-cell responses against herpes simplex virus 
type 1. J Virol (2004) 78:13082–9. doi:10.1128/JVI.78.23.13082-13089.2004 
32. Kursar M, Bonhagen K, Fensterle J, Kohler A, Hurwitz R, Kamradt T, et al. 
Regulatory CD4+CD25+ T cells restrict memory CD8+ T cell responses. J 
Exp Med (2002) 196:1585–92. doi:10.1084/jem.20011347 
33. Mendez S, Reckling SK, Piccirillo CA, Sacks D, Belkaid Y. Role for CD4(+) 
CD25(+) regulatory T cells in reactivation of persistent leishmaniasis and 
control of concomitant immunity. J Exp Med (2004) 200:201–10. doi:10.1084/
jem.20040298 
34. Suvas S, Kumaraguru U, Pack CD, Lee S, Rouse BT. CD4+CD25+ T cells 
regulate virus-specific primary and memory CD8+ T cell responses. J Exp 
Med (2003) 198:889–901. doi:10.1084/jem.20030171 
35. Badovinac VP, Harty JT. Programming, demarcating, and manip-
ulating CD8+ T-cell memory. Immunol Rev (2006) 211:67–80. 
doi:10.1111/j.0105-2896.2006.00384.x 
36. Wong P, Lara-Tejero M, Ploss A, Leiner I, Pamer EG. Rapid development of T cell 
memory. J Immunol (2004) 172:7239–45. doi:10.4049/jimmunol.172.12.7239 
37. Buchholz VR, Flossdorf M, Hensel I, Kretschmer L, Weissbrich B, Graf P, et al. 
Disparate individual fates compose robust CD8+ T cell immunity. Science 
(2013) 340:630–5. doi:10.1126/science.1235454 
38. Gett AV, Sallusto F, Lanzavecchia A, Geginat J. T cell fitness determined by 
signal strength. Nat Immunol (2003) 4:355–60. doi:10.1038/ni908 
39. Masopust D, Kaech SM, Wherry EJ, Ahmed R. The role of programming 
in memory T-cell development. Curr Opin Immunol (2004) 16:217–25. 
doi:10.1016/j.coi.2004.02.005 
40. Klenerman P, Hill A. T cells and viral persistence: lessons from diverse infec-
tions. Nat Immunol (2005) 6:873–9. doi:10.1038/ni1241 
September 2015 | Volume 6 | Article 51012
Qin et al. Treg early regulation of immunogenicity
Frontiers in Immunology | www.frontiersin.org
41. Wherry EJ, Ahmed R. Memory CD8 T-cell differentiation during viral infec-
tion. J Virol (2004) 78:5535–45. doi:10.1128/JVI.78.11.5535-5545.2004 
42. Hovav AH, Panas MW, Rahman S, Sircar P, Gillard G, Cayabyab MJ, et al. 
Duration of antigen expression in vivo following DNA immunization mod-
ifies the magnitude, contraction, and secondary responses of CD8+ T lym-
phocytes. J Immunol (2007) 179:6725–33. doi:10.4049/jimmunol.179.10.6725 
43. Altfeld M, Rosenberg ES. The role of CD4(+) T helper cells in the cytotoxic 
T lymphocyte response to HIV-1. Curr Opin Immunol (2000) 12:375–80. 
doi:10.1016/S0952-7915(00)00103-5 
44. Sun JC, Williams MA, Bevan MJ. CD4+ T cells are required for the mainte-
nance, not programming, of memory CD8+ T cells after acute infection. Nat 
Immunol (2004) 5:927–33. doi:10.1038/ni1105 
45. Northrop JK, Shen H. CD8+ T-cell memory: only the good ones last. Curr 
Opin Immunol (2004) 16:451–5. doi:10.1016/j.coi.2004.05.004 
46. Bourgeois C, Rocha B, Tanchot C. A role for CD40 expression on CD8+ T 
cells in the generation of CD8+ T cell memory. Science (2002) 297:2060–3. 
doi:10.1126/science.1072615 
47. Sercan O, Hammerling GJ, Arnold B, Schuler T. Innate immune cells contrib-
ute to the IFN-gamma-dependent regulation of antigen-specific CD8+ T cell 
homeostasis. J Immunol (2006) 176:735–9. doi:10.4049/jimmunol.176.2.735 
48. Whitmire JK, Benning N, Whitton JL. Cutting edge: early IFN-gamma sig-
naling directly enhances primary antiviral CD4+ T cell responses. J Immunol 
(2005) 175:5624–8. doi:10.4049/jimmunol.175.9.5624 
49. Whitmire JK, Tan JT, Whitton JL. Interferon-gamma acts directly on CD8+ 
T cells to increase their abundance during virus infection. J Exp Med (2005) 
201:1053–9. doi:10.1084/jem.20041463 
50. D’Souza WN, Schluns KS, Masopust D, Lefrancois L. Essential role for IL-2 
in the regulation of antiviral extralymphoid CD8 T cell responses. J Immunol 
(2002) 168:5566–72. doi:10.4049/jimmunol.168.11.5566 
51. Schoenberger SP, Janssen EM. IL-2 gets with the program. Nat Immunol 
(2006) 7:798–800. doi:10.1038/ni0806-798 
52. Williams MA, Tyznik AJ, Bevan MJ. Interleukin-2 signals during priming are 
required for secondary expansion of CD8+ memory T cells. Nature (2006) 
441:890–3. doi:10.1038/nature04790 
53. Barouch DH, Santra S, Tenner-Racz K, Racz P, Kuroda MJ, Schmitz JE, et al. 
Potent CD4+ T cell responses elicited by a bicistronic HIV-1 DNA vaccine 
expressing gp120 and GM-CSF. J Immunol (2002) 168:562–8. doi:10.4049/
jimmunol.168.2.562 
54. Seaman MS, Peyerl FW, Jackson SS, Lifton MA, Gorgone DA, Schmitz JE, et al. 
Subsets of memory cytotoxic T lymphocytes elicited by vaccination influence 
the efficiency of secondary expansion in  vivo. J Virol (2004) 78:206–15. 
doi:10.1128/JVI.78.1.206-215.2004 
55. Takahashi H, Nakagawa Y, Pendleton CD, Houghten RA, Yokomuro K, 
Germain RN, et  al. Induction of broadly cross-reactive cytotoxic T cells 
recognizing an HIV-1 envelope determinant. Science (1992) 255:333–6. 
doi:10.1126/science.1372448 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2015 Qin, Jiang, Han and Letvin. This is an open-access article dis-
tributed under the terms of the Creative Commons Attribution License (CC BY). 
The use, distribution or reproduction in other forums is permitted, provided 
the original author(s) or licensor are credited and that the original publication 
in this journal is cited, in accordance with accepted academic practice. No use, 
distribution or reproduction is permitted which does not comply with these 
terms.
